{"disease":{"id":"glanzmann-thrombasthenia","name":"glanzmann thrombasthenia"},"drugs":{"marketed":[{"drug_id":"eptacog-alfa-activated","indication_name":"Glanzmann's thrombasthenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eptacog Alfa","generic_name":"EPTACOG ALFA (ACTIVATED)","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT04119908","title":"Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06204042","title":"Multinational Glanzmann Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05315232","title":"The Experiences of People Who Live With Glanzmanns Thrombasthenia.","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Haemnet","has_results":false},{"nct_id":"NCT02179359","title":"Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","phase":"NA","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04595617","title":"Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)","phase":"NA","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06234813","title":"Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04548791","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Catalyst Biosciences","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}